Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma

  • Technology appraisal guidance
  • TA462
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

January 2019: The commercial access agreement has been replaced by a patient access scheme. Sections 1.1, 2 and 5 have been updated.

ISBN: 978-1-4731-2611-4